Epigenetic upregulation of urokinase plasminogen activator promotes the tropism of mesenchymal stem cells for tumor cells

Molecular Cancer Research

Volumn 8, Issue 8, 2010, Pages 1074-1083

  Pulukuri, Sai Murali Krishna ^a   Gorantla, Bharathi ^a   Dasari, Venkata Ramesh ^a   Gondi, Christopher S ^a   Rao, Jasti S ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; MESSENGER RNA; TRICHOSTATIN A; UROKINASE;

ARTICLE; BONE MARROW; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; DEACETYLATION; EPIGENETICS; GENETIC REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TUMOR CELL; TUMOR GENE; UMBILICAL CORD BLOOD; UPREGULATION;

ACETYLATION; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE; CELL MOVEMENT; CHROMATIN IMMUNOPRECIPITATION; EPIGENESIS, GENETIC; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; KIDNEY; MALE; MESENCHYMAL STEM CELLS; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TROPISM; UP-REGULATION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77955741862     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0495     Document Type: Article

References (39)

1. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003;3:489-501.
2. Buzanska L, Machaj EK, Zablocka B, Pojda Z, Domanska-Janik K. Human cord blood-derived cells attain neuronal and glial features in vitro. J Cell Sci 2002;115:2131-8. (Pubitemid 34746379)
3. Chen N, Hudson JE, Walczak P, et al. Human umbilical cord blood progenitors: the potential of these hematopoietic cells to become neural. Stem Cells 2005;23:1560-70. (Pubitemid 41741005)
4. Kramm CM, Sena-Esteves M, Barnett FH, et al. Gene therapy for brain tumors. Brain Pathol 1995;5:345-81.
5. Nakamizo A, Marini F, Amano T, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005;65:3307-18. (Pubitemid 40524615)
6. Newman MB, Willing AE, Manresa JJ, Sanberg CD, Sanberg PR. Cytokines produced by cultured human umbilical cord blood (HUCB) cells: implications for brain repair. Exp Neurol 2006; 199:201-8.
7. Pereboeva L, Komarova S, Mikheeva G, Krasnykh V, Curiel DT. Approaches to utilize mesenchymal progenitor cells as cellular vehicles. Stem Cells 2003;21:389-404. (Pubitemid 36793483)
8. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-β delivery into tumors. Cancer Res 2002;62:3603-8. (Pubitemid 34728832)
9. Son BR, Marquez-Curtis LA, Kucia M, et al. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-cmet axes and involves matrix metalloproteinases. Stem Cells 2006; 24:1254-64. (Pubitemid 44464694)
10. Sordi V, Malosio ML, Marchesi F, et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005;106:419-27. (Pubitemid 40981232)
11. Wynn RF, Hart CA, Corradi-Perini C, et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 2004;104:2643-5. (Pubitemid 39434942)
12. Ziu M, Schmidt NO, Cargioli TG, Aboody KS, Black PM, Carroll RS. Glioma-produced extracellular matrix influences brain tumor tropism of human neural stem cells. J Neurooncol 2006;79:125-33. (Pubitemid 44349939)
13. Jo M, Thomas KS, Somlyo AV, Somlyo AP, Gonias SL. Cooperativity between the Ras-ERK and Rho-Rho kinase pathways in urokinase-type plasminogen activator-stimulated cell migration. J Biol Chem 2002;277:12479-85. (Pubitemid 34952823)
14. Marks PA, Rifkind RA, Richon VM, Breslow R. Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin Cancer Res 2001;7:759-60. (Pubitemid 32708707)
15. Dasari VR, Spomar DG, Li L, Gujrati M, Rao JS, Dinh DH. Umbilical cord blood stem cell mediated downregulation of Fas improves functional recovery of rats after spinal cord injury. NeurochemRes 2008;33:134-49. (Pubitemid 350242800)
16. Pulukuri SM, Gorantla B, Rao JS. Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator (uPA). J Biol Chem 2007;282: 35594-603. (Pubitemid 350277094)
17. Yanamandra N, Kondraganti S, Gondi CS, et al. Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int J Cancer 2005;115:998-1005. (Pubitemid 40791841)
18. Pulukuri SM, Gondi CS, Lakka SS, et al. RNA Interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005;280: 36529-40.
19. De Felice L, Tatarelli C, Mascolo MG, et al. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res 2005;65:1505-13. (Pubitemid 40270180)
20. Gregory RI, O'Neill LP, Randall TE, et al. Inhibition of histone deacetylases alters allelic chromatin conformation at the imprinted U2af1-1 locus in mouse embryonic stem cells. J Biol Chem 2002; 277:11728-34.
21. Pulukuri SM, Rao JS. Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis. Cancer Res 2007;67:6637-46.
22. Gutova M, Najbauer J, Frank RT, et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells 2008;26: 1406-13.
23. Akashi K. Lineage promiscuity and plasticity in hematopoietic development. Ann N Y Acad Sci 2005;1044:125-31. (Pubitemid 40967602)
24. Attema JL, Papathanasiou P, Forsberg EC, Xu J, Smale ST, Weissman IL. Epigenetic characterization of hematopoietic stem cell differentiation using miniChIP and bisulfite sequencing analysis. Proc Natl Acad Sci U S A 2007;104:12371-6. (Pubitemid 47206144)
25. Xi R, Xie T. Stem cell self-renewal controlled by chromatin remodeling factors. Science 2005;310:1487-9.
26. Geiman TM, Robertson KD. Chromatin remodeling, histone modifications, and DNA methylation - How does it all fit together? J Cell Biochem 2002;87:117-25.
27. Della RF, Criniti V, Della P V, et al. Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS Lett 2001; 499:199-204.
28. Tan NC, Tan DY, Tan LC. An unusual headache: Lemierre's syndrome. J Neurol 2003;250:245-6.
29. Davie JR, Spencer VA. Control of histone modifications. J Cell Biochem 1999;Suppl 32-33:141-8.
30. Pazin MJ, Kadonaga JT. What's up and down with histone deacetylation and transcription? Cell 1997;89:325-8.
31. Kargiotis O, Chetty C, Gogineni V, et al. uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo. Int J Oncol 2008;33:937-47.
32. Salvi A, Arici B, De Petro G, Barlati S. Small interfering RNA urokinase silencing inhibits invasion and migration of human hepatocellular carcinoma cells. Mol Cancer Ther 2004;3:671-8. (Pubitemid 39193747)
33. Schweinitz A, Steinmetzer T, Banke IJ, et al. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 2004;279:33613-22. (Pubitemid 39063010)
34. Yamamoto M, Sawaya R, Mohanam S, et al. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res 1994;54:3656-61. (Pubitemid 24241173)
35. Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000;12:613-20.
36. Nguyen DH, Hussaini IM, Gonias SL. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 1998;273:8502-7.
37. Nguyen DH, Webb DJ, Catling AD, et al. Urokinase-type plasminogen activator stimulates the Ras/extracellular signal-regulated kinase (ERK) signaling pathway and MCF-7 cell migration by a mechanism that requires focal adhesion kinase, Src, and Shc. Rapid dissociation of GRB2/Sps-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells. J Biol Chem2000;275:19382-8.
38. Kiyan J, Kiyan R, Haller H, Dumler I. Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-β. EMBO J 2005;24:1787-97. (Pubitemid 40769498)
39. Jo M, Thomas KS, Marozkina N, et al. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. J Biol Chem 2005;280:17449-57. (Pubitemid 41389216)